What are the major opportunities in the Neuroendocrine Carcinoma market? What are the strategies for the Neuroendocrine Carcinoma market?

For detailed insights on the major opportunities and strategies in the Neuroendocrine Carcinoma market, Read More

How does the Neuroendocrine Carcinoma market relate to the overall economy and other similar markets?

For detailed insights on the key dynamics influencing the Neuroendocrine Carcinoma market growth and SWOT analysis of the Neuroendocrine Carcinoma industry, Read More

For detailed insights on the mergers and acquisitions in the Neuroendocrine Carcinoma industry,

What are the key dynamics influencing the Neuroendocrine Carcinoma market growth? SWOT analysis of the Neuroendocrine Carcinoma market. Read More

Global Neuroendocrine Carcinoma Market Report 2025

Item added to cart!

Published : December 2025

Pages : 175

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Purchase This Report Download Sample PDF

Purchase This Report

Neuroendocrine Carcinoma Global Market Report 2025

Name: Neuroendocrine Carcinoma Global Market Report 2025
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

By Type (Gastroenteropancreatic Neuroendocrine Tumors, Carcinoid Tumors, Pheochromocytoma, Medullary Thyroid Carcinoma), By Diagnostic Tools (Imaging, Biopsy, Serology), By Treatment (Chemotherapy, Radiotherapy, Surgery, Other Treatments), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End-User (Hospitals, Clinics, Oncology Centers, Ambulatory Surgery Centers) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Neuroendocrine Carcinoma Market Overview

• Neuroendocrine Carcinoma market size has reached to $1.63 billion in 2024

• Expected to grow to $2.31 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%

• Growth Driver: Growth Of Targeted Therapies Driving The Market Expansion

• Market Trend: Advancements In Targeted Radiopharmaceutical Therapy For Neuroendocrine Carcinoma Treatment

• North America was the largest region in 2024 and Asia-Pacific is the fastest growing region.

What Is Covered Under Neuroendocrine Carcinoma Market?

Neuroendocrine carcinoma (NEC) refers to a rare and aggressive type of cancer that originates in neuroendocrine cells, which have traits of both nerve cells and hormone-producing cells. They are used for identifying and treating tumors that can develop in various organs, including the lungs, pancreas, and gastrointestinal tract, often requiring a combination of surgery, chemotherapy, and targeted therapies.

The main types of neuroendocrine carcinoma are gastroenteropancreatic neuroendocrine tumors, carcinoid tumors, pheochromocytoma, and medullary thyroid carcinoma. Gastroenteropancreatic neuroendocrine tumors are rare malignancies originating from neuroendocrine cells in the gastrointestinal tract or pancreas. It includes various diagnostic tools such as imaging, biopsy, and serology, with several treatments including chemotherapy, radiotherapy, surgery, and others. It is distributed through various distribution channels, such as hospital pharmacies, retail pharmacies, and online pharmacies, and used by several end users, including hospitals, clinics, oncology centers, and ambulatory surgery centers.

Neuroendocrine Carcinoma Market Size and growth rate 2025 to 2029: Graph

What Is The Neuroendocrine Carcinoma Market Size 2025 And Growth Rate?

What Is The Neuroendocrine Carcinoma Market Growth Forecast?

The neuroendocrine carcinoma market size is expected to see strong growth in the next few years. It will grow to $2.31 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to the increasing incidence rate of cancer disease, increasing rate of product approval, rising usage of improved diagnostic imaging methods, growth of targeted therapies, and increasing rate of diagnosis and treatment options available. Major trends in the forecast period include the advancement in diagnostic technologies, enhanced imaging technologies, targeted treatment approaches, advancements in neuroendocrine tumor management, and the advancement in targeted therapies and immunotherapies.

The forecast of 7.2% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. cancer centers by driving up the cost of somatostatin analog therapies and peptide receptor radionuclide agents imported from Switzerland and Italy, exacerbating treatment delays and increasing nuclear medicine department costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Book your 30 minutes free consultation with our research experts

What’s The Trade War Impact On Healthcare Services Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

How Is The Neuroendocrine Carcinoma Market Segmented?

1) By Type: Gastroenteropancreatic Neuroendocrine Tumors, Carcinoid Tumors, Pheochromocytoma, Medullary Thyroid Carcinoma

2) By Diagnostic Tools: Imaging, Biopsy, Serology

3) By Treatment: Chemotherapy, Radiotherapy, Surgery, Other Treatments

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Clinics, Oncology Centers, Ambulatory Surgery Centers

Subsegments:

1) By Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Pancreatic Neuroendocrine Tumors (pNETs), Small Intestinal Neuroendocrine Tumors, Gastric Neuroendocrine Tumors, Colorectal Neuroendocrine Tumors

2) By Carcinoid Tumors: Pulmonary Carcinoid Tumors, Gastrointestinal Carcinoid Tumors

3) By Pheochromocytoma: Adrenal Pheochromocytoma, Extra-Adrenal Paraganglioma

4) By Medullary Thyroid Carcinoma: Sporadic Medullary Thyroid Carcinoma, Hereditary Medullary Thyroid Carcinoma (MEN2-Associated)

What Is Driving The Neuroendocrine Carcinoma Market? Growth Of Targeted Therapies Driving The Market Expansion

The growth of targeted therapies is expected to propel the growth of the neuroendocrine carcinoma market going forward. Targeted therapies are treatments designed to precisely address and disrupt the molecular processes or genetic alterations that cause a disease, especially cancer. The demand for targeted therapies rises due to factors such as their precision in treating specific genetic mutations, advancements in personalized medicine, and better patient outcomes with fewer side effects. Neuroendocrine carcinoma enables the development of targeted therapies that specifically address the tumor’s genetic and biochemical profiles, enhancing treatment precision and effectiveness. For instance, in July 2023, according to the report published by the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, at the end of Q1 2023, there were 247 gene therapies in Phase II, but this number rose by 5% to reach 260 by the end of Q2. Therefore, the growth of targeted therapies is driving the growth of the neuroendocrine carcinoma industry.

Who Are The Major Players In The Global Neuroendocrine Carcinoma Market?

Major companies operating in the neuroendocrine carcinoma market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Amgen Inc., Boehringer Ingelheim GmbH, Exelixis Inc., Lantheus Holdings Inc., HUTCHMED Limited, Dana-Farber Cancer Institute Inc., Abdera Therapeutics Inc., Orano Med S.A, Eckert & Ziegler Radiopharma GmbH, Callisto Pharmaceuticals Inc., RadioMedix Inc., Clarity Pharmaceuticals Limited, Delcath Systems Inc., Provectus Biopharmaceuticals Inc.

What Are The Key Trends Of The Global Neuroendocrine Carcinoma Market? Advancements In Targeted Radiopharmaceutical Therapy For Neuroendocrine Carcinoma Treatment

Major companies operating in the neuroendocrine carcinoma market are focusing on developing advanced therapies, such as targeted radiopharmaceutical therapy, to improve treatment precision and patient outcomes. Targeted radiopharmaceutical therapy involves using radioactive molecules that specifically target and deliver radiation to cancer cells, minimizing harm to healthy tissue. For instance, in September 2024, Abdera Therapeutics Inc., a Canada-based biotechnology company, received the Food and Drug Administration (FDA)-granted orphan drug designation for ABD-147 for the treatment of neuroendocrine carcinoma. It is designed to selectively target tumors expressing the DLL3 protein, commonly upregulated in aggressive neuroendocrine cancers such as small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). This designation offers significant development advantages, including tax credits for clinical trials and the potential for market exclusivity, positioning ABD-147 as a promising treatment in this specialized oncology space.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The Neuroendocrine Carcinoma Market? Bristol-Myers Squibb Acquired RayzeBio To Enhance Oncology Pipeline With Targeted Radiopharmaceuticals

In February 2024, Bristol-Myers Squibb Company, a US-based pharmaceutical company, acquired RayzeBio, Inc. for $4.1 billion. With this acquisition, Bristol-Myers Squibb aims to strengthen its oncology pipeline, particularly in the treatment of neuroendocrine tumors and other hard-to-treat cancers, by leveraging RayzeBio's expertise in targeted therapies and innovative drug development. RayzeBio Inc. is a US-based company that provides treatment for gastroenteropancreatic neuroendocrine tumors.

What Is The Regional Outlook For The Global Neuroendocrine Carcinoma Market?

North America was the largest region in the neuroendocrine carcinoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Neuroendocrine Carcinoma Market?

The neuroendocrine carcinoma market consists of revenues earned by entities by providing services such as hormonal symptom management, long-term care plans, pain management, immunotherapy, and targeted therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The neuroendocrine carcinoma market also consists of sales of products including somatostatin analogs, positron emission tomography (PET) scanners, needles and equipment, infusion pumps, and drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Neuroendocrine Carcinoma Industry?

The neuroendocrine carcinoma market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the neuroendocrine carcinoma industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abdul Wasay

Neuroendocrine Carcinoma Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$1.75 billion
Revenue Forecast In 2034	$2.31 billion
Growth Rate	CAGR of 7.2% from 2025 to 2034
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	The neuroendocrine carcinoma market covered in this report is segmented – 1) By Type: Gastroenteropancreatic Neuroendocrine Tumors, Carcinoid Tumors, Pheochromocytoma, Medullary Thyroid Carcinoma 2) By Diagnostic Tools: Imaging, Biopsy, Serology 3) By Treatment: Chemotherapy, Radiotherapy, Surgery, Other Treatments 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 5) By End-User: Hospitals, Clinics, Oncology Centers, Ambulatory Surgery Centers Subsegments: 1) By Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Pancreatic Neuroendocrine Tumors (pNETs), Small Intestinal Neuroendocrine Tumors, Gastric Neuroendocrine Tumors, Colorectal Neuroendocrine Tumors 2) By Carcinoid Tumors: Pulmonary Carcinoid Tumors, Gastrointestinal Carcinoid Tumors 3) By Pheochromocytoma: Adrenal Pheochromocytoma, Extra-Adrenal Paraganglioma 4) By Medullary Thyroid Carcinoma: Sporadic Medullary Thyroid Carcinoma, Hereditary Medullary Thyroid Carcinoma (MEN2-Associated)
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Amgen Inc., Boehringer Ingelheim GmbH, Exelixis Inc., Lantheus Holdings Inc., HUTCHMED Limited, Dana-Farber Cancer Institute Inc., Abdera Therapeutics Inc., Orano Med S.A, Eckert & Ziegler Radiopharma GmbH, Callisto Pharmaceuticals Inc., RadioMedix Inc., Clarity Pharmaceuticals Limited, Delcath Systems Inc., Provectus Biopharmaceuticals Inc.
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Neuroendocrine Carcinoma Market Characteristics

3. Neuroendocrine Carcinoma Market Trends And Strategies

4. Neuroendocrine Carcinoma Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Neuroendocrine Carcinoma Growth Analysis And Strategic Analysis Framework

5.1. Global Neuroendocrine Carcinoma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Neuroendocrine Carcinoma Market Growth Rate Analysis

5.4. Global Neuroendocrine Carcinoma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Neuroendocrine Carcinoma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Neuroendocrine Carcinoma Total Addressable Market (TAM)

6. Neuroendocrine Carcinoma Market Segmentation

6.1. Global Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Gastroenteropancreatic Neuroendocrine Tumors

Carcinoid Tumors

Pheochromocytoma

Medullary Thyroid Carcinoma

6.2. Global Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Imaging

Biopsy

Serology

6.3. Global Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Chemotherapy

Radiotherapy

Surgery

Other Treatments

6.4. Global Neuroendocrine Carcinoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

6.5. Global Neuroendocrine Carcinoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Clinics

Oncology Centers

Ambulatory Surgery Centers

6.6. Global Neuroendocrine Carcinoma Market, Sub-Segmentation Of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Pancreatic Neuroendocrine Tumors (pNETs)

Small Intestinal Neuroendocrine Tumors

Gastric Neuroendocrine Tumors

Colorectal Neuroendocrine Tumors

6.7. Global Neuroendocrine Carcinoma Market, Sub-Segmentation Of Carcinoid Tumors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Pulmonary Carcinoid Tumors

Gastrointestinal Carcinoid Tumors

6.8. Global Neuroendocrine Carcinoma Market, Sub-Segmentation Of Pheochromocytoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Adrenal Pheochromocytoma

Extra-Adrenal Paraganglioma

6.9. Global Neuroendocrine Carcinoma Market, Sub-Segmentation Of Medullary Thyroid Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Sporadic Medullary Thyroid Carcinoma

Hereditary Medullary Thyroid Carcinoma (MEN2-Associated)

7. Neuroendocrine Carcinoma Market Regional And Country Analysis

7.1. Global Neuroendocrine Carcinoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Neuroendocrine Carcinoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Neuroendocrine Carcinoma Market

8.1. Asia-Pacific Neuroendocrine Carcinoma Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Neuroendocrine Carcinoma Market

9.1. China Neuroendocrine Carcinoma Market Overview

9.2. China Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Neuroendocrine Carcinoma Market

10.1. India Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Neuroendocrine Carcinoma Market

11.1. Japan Neuroendocrine Carcinoma Market Overview

11.2. Japan Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Neuroendocrine Carcinoma Market

12.1. Australia Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Neuroendocrine Carcinoma Market

13.1. Indonesia Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Neuroendocrine Carcinoma Market

14.1. South Korea Neuroendocrine Carcinoma Market Overview

14.2. South Korea Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Neuroendocrine Carcinoma Market

15.1. Western Europe Neuroendocrine Carcinoma Market Overview

15.2. Western Europe Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Neuroendocrine Carcinoma Market

16.1. UK Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Neuroendocrine Carcinoma Market

17.1. Germany Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Neuroendocrine Carcinoma Market

18.1. France Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Neuroendocrine Carcinoma Market

19.1. Italy Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Neuroendocrine Carcinoma Market

20.1. Spain Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Neuroendocrine Carcinoma Market

21.1. Eastern Europe Neuroendocrine Carcinoma Market Overview

21.2. Eastern Europe Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Neuroendocrine Carcinoma Market

22.1. Russia Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Neuroendocrine Carcinoma Market

23.1. North America Neuroendocrine Carcinoma Market Overview

23.2. North America Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Neuroendocrine Carcinoma Market

24.1. USA Neuroendocrine Carcinoma Market Overview

24.2. USA Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Neuroendocrine Carcinoma Market

25.1. Canada Neuroendocrine Carcinoma Market Overview

25.2. Canada Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Neuroendocrine Carcinoma Market

26.1. South America Neuroendocrine Carcinoma Market Overview

26.2. South America Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Neuroendocrine Carcinoma Market

27.1. Brazil Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Neuroendocrine Carcinoma Market

28.1. Middle East Neuroendocrine Carcinoma Market Overview

28.2. Middle East Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Neuroendocrine Carcinoma Market

29.1. Africa Neuroendocrine Carcinoma Market Overview

29.2. Africa Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Neuroendocrine Carcinoma Market Competitive Landscape And Company Profiles

30.1. Neuroendocrine Carcinoma Market Competitive Landscape

30.2. Neuroendocrine Carcinoma Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Neuroendocrine Carcinoma Market Other Major And Innovative Companies

31.1. Novartis AG

31.2. Amgen Inc.

31.3. Boehringer Ingelheim GmbH

31.4. Exelixis Inc.

31.5. Lantheus Holdings Inc.

31.6. HUTCHMED Limited

31.7. Dana-Farber Cancer Institute Inc.

31.8. Abdera Therapeutics Inc.

31.9. Orano Med S.A

31.10. Eckert & Ziegler Radiopharma GmbH

31.11. Callisto Pharmaceuticals Inc.

31.12. RadioMedix Inc.

31.13. Clarity Pharmaceuticals Limited

31.14. Delcath Systems Inc.

31.15. Provectus Biopharmaceuticals Inc.

32. Global Neuroendocrine Carcinoma Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neuroendocrine Carcinoma Market

34. Recent Developments In The Neuroendocrine Carcinoma Market

35. Neuroendocrine Carcinoma Market High Potential Countries, Segments and Strategies

35.1 Neuroendocrine Carcinoma Market In 2029 - Countries Offering Most New Opportunities

35.2 Neuroendocrine Carcinoma Market In 2029 - Segments Offering Most New Opportunities

35.3 Neuroendocrine Carcinoma Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Neuroendocrine Carcinoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Neuroendocrine Carcinoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global Neuroendocrine Carcinoma Market, Sub-Segmentation Of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global Neuroendocrine Carcinoma Market, Sub-Segmentation Of Carcinoid Tumors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Global Neuroendocrine Carcinoma Market, Sub-Segmentation Of Pheochromocytoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Global Neuroendocrine Carcinoma Market, Sub-Segmentation Of Medullary Thyroid Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Global Neuroendocrine Carcinoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: Global Neuroendocrine Carcinoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: Asia-Pacific, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: Asia-Pacific, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: Asia-Pacific, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: China, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: China, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: China, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: India, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: India, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: India, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Japan, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Japan, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Japan, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Australia, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Australia, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Australia, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: Indonesia, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: Indonesia, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: Indonesia, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: South Korea, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: South Korea, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: South Korea, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: Western Europe, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: Western Europe, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: Western Europe, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: UK, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: UK, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: UK, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: Germany, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: Germany, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: Germany, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: France, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: France, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: France, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: Italy, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Italy, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Italy, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Spain, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Spain, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Spain, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Eastern Europe, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Eastern Europe, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Eastern Europe, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: Russia, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: Russia, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: Russia, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: North America, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: North America, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: North America, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: USA, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: USA, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: USA, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: Canada, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: Canada, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: Canada, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: South America, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: South America, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: South America, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: Brazil, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Brazil, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Brazil, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Middle East, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Middle East, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Middle East, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 77: Africa, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 78: Africa, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 79: Africa, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 80: Pfizer Inc. Financial Performance

Table 81: Merck & Co. Inc. Financial Performance

Table 82: AbbVie Inc. Financial Performance

Table 83: Bristol-Myers Squibb Company Financial Performance

Table 84: AstraZeneca plc Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Neuroendocrine Carcinoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Neuroendocrine Carcinoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global Neuroendocrine Carcinoma Market, Sub-Segmentation Of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global Neuroendocrine Carcinoma Market, Sub-Segmentation Of Carcinoid Tumors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Global Neuroendocrine Carcinoma Market, Sub-Segmentation Of Pheochromocytoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Global Neuroendocrine Carcinoma Market, Sub-Segmentation Of Medullary Thyroid Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Global Neuroendocrine Carcinoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: Global Neuroendocrine Carcinoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: Asia-Pacific, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: Asia-Pacific, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: Asia-Pacific, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: China, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: China, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: China, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: India, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: India, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: India, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Japan, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Japan, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Japan, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Australia, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Australia, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Australia, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: Indonesia, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: Indonesia, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: Indonesia, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: South Korea, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: South Korea, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: South Korea, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: Western Europe, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: Western Europe, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: Western Europe, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: UK, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: UK, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: UK, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: Germany, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: Germany, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: Germany, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: France, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: France, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: France, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: Italy, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Italy, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Italy, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Spain, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Spain, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Spain, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Eastern Europe, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Eastern Europe, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Eastern Europe, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: Russia, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: Russia, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: Russia, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: North America, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: North America, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: North America, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: USA, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: USA, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: USA, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: Canada, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: Canada, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: Canada, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: South America, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: South America, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: South America, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: Brazil, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Brazil, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Brazil, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Middle East, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Middle East, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Middle East, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 77: Africa, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 78: Africa, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 79: Africa, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 80: Pfizer Inc. Financial Performance

Figure 81: Merck & Co. Inc. Financial Performance

Figure 82: AbbVie Inc. Financial Performance

Figure 83: Bristol-Myers Squibb Company Financial Performance

Figure 84: AstraZeneca plc Financial Performance

Next-Gen Primary Health Care Service : Market Forecast, Transformation, and Long-Term Trajectories

Progressive Ataxia And Weakness Disorders Growth Trajectory: Key Forecasts and Strategic Insights

Prostate Cancer Nuclear Medicine Diagnostics Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

Emerging Trends Redefining the Prostate Cancer Nuclear Medicine Diagnostics Market Landscape: Automated Parallel Capillary Electrophoresis Systems Transforming Protein Analysis In The Protein Chip Market

A strategic 2025 report providing key insights, trends and forecasts for the global live attenuated polio vaccine market between 2025–2034.

A 2025 forecast report outlining growth projections, key trends and regulatory landscape of the medicated shampoo market through 2029.

A 2025 strategic report on market size, competitive landscape and expansion strategies in the medications for heart failure market.

Explore strategic insights and forecasts in the global virtual nutrition coach app market, offering competitive benchmarking and market growth trends.

Basal Cell Carcinoma Treatment Global Market Report 2025 – By Treatment (Surgery, Medication, Other Treatments), By Route Of Administration (Oral, Parenteral, Other Route Of Administrations), By Distribution Channel (Hos...

Adrenal Cancer Diagnostics Global Market Report 2025 – By Test (Magnetic Resonance Imaging (MRI), Computed Tomography (CT) Scan, X-ray, Positron Emission Tomography (PET) Scan, Biopsy), By Treatment (Surgery, Chemotherap...

Basal Cell Carcinoma Treatment Global Market Report 2025 – By Treatment (Surgery, Medication, Other Treatments), By Route Of Administration (Oral, Parenteral, Other Route Of Administrations), By Distribution Channel (Hos...

Pheochromocytoma Global Market Report 2025 – By Type (Adrenal Pheochromocytoma, Extra-Adrenal Pheochromocytoma), By Treatment (Medication, Surgery, Radionuclide Treatment, Other Treatments), By Diagnosis (Laboratory Test...

Adrenocortical Carcinoma Global Market Report 2025 – By Type (Localized Adrenocortical Carcinoma, Metastatic Adrenocortical Carcinoma), By Therapy (Surgery, Laparoscopic Surgery, Open Surgery, Chemotherapy, Targeted Ther...

Brain Tumor Drugs Global Market Report 2025 – By Drugs (Temozolomide, Bevacizumab, Other Drugs), By End User (Hospital Pharmacies, Retail Pharmacies/Drug Stores, Other End-Users) – Impact of Tariff and Trade War on Marke...

Appendiceal Cancer Treatment Global Market Report 2025 – By Type (Colonic-Type Adenocarcinoma, Mucinous Adenocarcinoma Of Appendix, Goblet Cell Adenocarcinoma, Neuroendocrine Carcinoma, Other Types), By Treatment (Surger...

Frequently Asked Questions

What is the definition of the Neuroendocrine Carcinoma market?

How will the Neuroendocrine Carcinoma market drivers and restraints affect the market dynamics? What forces will shape the Neuroendocrine Carcinoma industry going forward?

The market major growth driver - Growth Of Targeted Therapies Driving The Market Expansion. For further insights on this market, request a sample here

What is the forecast market size or the forecast market value of the Neuroendocrine Carcinoma market?

The neuroendocrine carcinoma market size has grown strongly in recent years. It will grow from $1.63 billion in 2024 to $1.75 billion in 2025 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to the rise of the imaging sector, an increase in the incidence of neuroendocrine tumors, increasing investments, increasing government initiatives, and demand for treatments for neuroendocrine tumors. The neuroendocrine carcinoma market size is expected to see strong growth in the next few years. It will grow to " $2.31 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to the increasing incidence rate of cancer disease, increasing rate of product approval, rising usage of improved diagnostic imaging methods, growth of targeted therapies, and increasing rate of diagnosis and treatment options available. Major trends in the forecast period include the advancement in diagnostic technologies, enhanced imaging technologies, targeted treatment approaches, advancements in neuroendocrine tumor management, and the advancement in targeted therapies and immunotherapies. For further insights on this market, request a sample here

How is the Neuroendocrine Carcinoma market segmented?

The neuroendocrine carcinomamarket covered in this report is segmented –
1) By Type: Gastroenteropancreatic Neuroendocrine Tumors; Carcinoid Tumors; Pheochromocytoma; Medullary Thyroid Carcinoma
2) By Diagnostic Tools: Imaging; Biopsy; Serology
3) By Treatment: Chemotherapy; Radiotherapy; Surgery; Other Treatments
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
5) By End-User: Hospitals; Clinics; Oncology Centers; Ambulatory Surgery Centers Subsegments:
1) By Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Pancreatic Neuroendocrine Tumors (pNETs); Small Intestinal Neuroendocrine Tumors; Gastric Neuroendocrine Tumors; Colorectal Neuroendocrine Tumors
2) By Carcinoid Tumors: Pulmonary Carcinoid Tumors; Gastrointestinal Carcinoid Tumors
3) By Pheochromocytoma: Adrenal Pheochromocytoma; Extra-Adrenal Paraganglioma
4) By Medullary Thyroid Carcinoma: Sporadic Medullary Thyroid Carcinoma; Hereditary Medullary Thyroid Carcinoma (MEN2-Associated) For further insights on this market, request a sample here

Which region has the largest share of the Neuroendocrine Carcinoma market? What are the other regions covered in the report?

North America was the largest region in the neuroendocrine carcinoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuroendocrine carcinoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Who are the major players in the Neuroendocrine Carcinoma market?

What are the key trends in the Neuroendocrine Carcinoma market?

Major trends in this market include Advancements In Targeted Radiopharmaceutical Therapy For Neuroendocrine Carcinoma Treatment. For further insights on this market, request a sample here.